Ocular Genomics
243 Charles Street Boston, MA 02114 Contact us
Diagnostic Testing
Support our research
Explore our labs
Ocular Genomics MENU
Ocular Genomics
  • Meet the Team
  • Services
    • Biobank Core Services
    • Bioinformatics and Statistics Core
    • Functional Genomics (Zebrafish) Core
    • Gene Transfer Vector
      • Rates
      • Order Information
      • Contact Us
    • Genetic Diagnostic Testing Service
      • Pricing
    • Genomics Core Services
      • Sample Processing
      • Sequencing
      • Other Genomics Services
    • IRD service
  • Labs
    • Amamoto lab
      • Lab Members
    • Biobank Core
    • Bujakowska Lab
      • Lab Members
      • Publications
    • Comander Lab
      • Lab Members
      • Publications
    • Engle Lab
    • Functional Genomics Core (Zebrafish Facility)
      • Lab Members
    • Genetic Counseling Team
      • Team Members
    • Genomics Core Lab
      • Lab Members
    • iPS Research Lab
      • Lab Members
      • Grant support
      • Publications
    • Liu Lab
      • Lab Members
      • Publications
      • Projects
    • Mary Whitman Lab
      • Lab Members
    • MEEI Bioinformatics Center (MBC)
      • Lab Members
    • Pierce Lab
      • Lab Members
      • Publications
      • Projects
    • Segrè Lab
      • Selected Publications
    • Vandenberghe Lab
      • Lab Members
    • Wiggs Lab
      • Lab Members
  • News & Publications
    • RETINAL Transcriptome
  • Affiliates
  • Careers
  • Home
  • News
  • Findings Published in Human Molecular Genetics

Recent Posts

  • Francesca Kim wins ARVO outstanding poster award
  • Friedenwald Award Lecture presented by OGI member Connie Cepko at ARVO 2025 annual meeting
  • Findings highlight the significance of Vascular Endothelial Protein Tyrosine Phosphatase in diverse ocular and systemic veno-vascular diseases.
  • Extracellular Vesicle RNAs as Biomarkers for Inherited Retinal Degenerations
  • BRILLIANCE Trial shows CRISPR Gene Editing Found Safe and Effective for Treating Patients with rare genetic disorder.

Archives

  • May 2025
  • March 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • July 2024
  • June 2024
  • May 2024
  • January 2024
  • October 2023
  • July 2023
  • June 2023
  • May 2023
  • March 2023
  • February 2023
  • December 2022
  • November 2022
  • June 2021
  • May 2021
  • March 2021
  • February 2021
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • June 2020
  • August 2019
  • May 2019
  • April 2019
  • May 2018
  • April 2018
  • March 2018
  • November 2017
  • September 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017

Categories

  • News
  • Publication

Findings Published in Human Molecular Genetics
May 1, 2017

Mass. Eye and Ear Researchers Report a Critical Role for the Complement System in Early Macular Degeneration Findings published in Human Molecular Genetics

BOSTON, Mass., August 14, 2013 − In a study published today in the journal of Human Molecular Genetics, Drs. Donita Garland, Rosario Fernandez-Godino, and Eric Pierce of the Ocular Genomics Institute, at the Massachusetts Eye and Ear Infirmary, Harvard Medical School, along with their colleagues, reported the unexpected finding that, in mice genetically engineered to have an inherited form of macular degeneration, turning off the animals’ complement system, a part of the immune system, prevented the disease.

Macular degenerations, which occur in several forms, are important causes of vision loss. Juvenile or early-onset macular degeneration includes several inherited disorders that can affect children and young adults. In contrast, age-related macular degeneration (AMD) affects older individuals; it is the leading cause of blindness for individuals over 65 years of age in developed countries, and its prevalence is increasing worldwide. Both inherited macular degeneration and AMD lead to the loss of central vision. While therapies exist for some forms of late AMD and nutritional supplements can slow the progression of early AMD for some patients, improved therapies to prevent vision loss from these disorders are needed.

This is the first report to demonstrate a role for the complement system in inherited macular degeneration. Previous genetic studies have shown that variants in the genes that encode several complement system components are important risk factors for AMD. Based on this, drugs that inhibit specific complement system activities are being tested clinically as treatments for AMD. However, it is not entirely clear how alterations in complement system components lead to AMD.

The new results reported suggest that complement activation by abnormalities in the extracellular matrix or the scaffold secreted by retinal cells plays an important role in the formation of basal deposits, one of the earliest stages of macular degeneration. Basal deposits are precursors of drusen, which appear as spots in the retina on clinical examination, and are accumulations of proteins and lipids outside the retinal cells; their presence is the first clinical indication of a risk of developing macular degeneration.

The findings are important because they suggest that inherited macular degenerations share common features with AMD, such as a complement-mediated response to abnormal extracellular matrix. The results also suggest that alterations in the activity of the complement system are involved in the earliest stages of disease pathogenesis. This finding has important implications for the use of drugs that modulate the complement system for treating macular degenerations.

For these studies, the investigators used a mouse model of the inherited macular dystrophy Doyne Honeycomb Retinal Dystrophy/Malattia Leventinese (DHRD/ML), which is caused by the p.Arg345Trp mutation in the EFEMP1 gene. This mutation leads to extensive drusen in patients with DHRD/ML, and the gene targeted EFEMP1R345W/R345W mice develop extensive basal deposits.

As a first step in their studies, Dr. Garland and colleagues used proteomic techniques to identify the proteins present in the basal deposits of the EFEMP1R345W/R345W mice. As they do in people, these deposits form between the retinal pigment epithelial cells and their basement membrane, which is called Bruch’s membrane and is composed of extracellular matrix. These studies showed that the basal deposits are composed of normal extracellular matrix components that are present in abnormal amounts. This is logical because the EFEMP1 protein is secreted by retinal cells and is thought to be required for maturation of elastin fibers, which are part of Bruch’s membrane.

The proteomic analyses also suggest that the altered extracellular matrix stimulates a local immune response, including activation of the complement system. The complement system is part of our innate immune system, and helps fend off infections, but under certain circumstances can also lead to cell and tissue damage.

The Mass. Eye and Ear team applied the power of mouse genetics to study the role of complement in basal deposit formation, and generated EFEMP1R345W/R345W:C3-/- double mutant mice, which have the disease-causing mutation in EFEMP1 and also lack the key complement component C3. Without C3, the complement system cannot be activated. In contrast to their single mutant EFEMP1-R345W cousins, the double mutant EFEMP1R345W/R345W:C3-/- mice did not develop basal deposits, demonstrating that the complement system is required for formation of basal deposits.

The investigators plan to continue their studies to help identify additional treatments to prevent vision loss from macular degenerations.

Reference:

Title: Mouse genetics and proteomic analyses demonstrate a critical role for complement in a model of DHRD/ML, an inherited macular degeneration

Authors: Donita L. Garland, Rosario Fernandez-Godino, Inderjeet Kaur, Kaye D. Speicher, James M. Harnly, John D. Lambris, David W. Speicher, Eric A. Pierce

Journal: Human Molecular Genetics

Abstract

PDF

Grant support: This work was supported by grants from the Rosanne Silbermann Foundation, Research to Prevent Blindness, and the Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School.

Featured:

Contact Us

243 Charles Street
Boston, MA 02114

Labs

  • Amamoto lab
  • Biobank Core
  • Bujakowska Lab
  • Comander Lab
  • Engle Lab
  • Functional Genomics Core (Zebrafish Facility)
  • Genetic Counseling Team
  • Genomics Core Lab
  • iPS Research Lab
  • Liu Lab
  • Pierce Lab
  • Segrè Lab
  • Vandenberghe Lab
  • Whitman Lab
  • Wiggs Lab

Sitemap

  • Affiliates
  • Careers
  • Meet the Team
  • News & publications
  • Support Our Research
  • Services
  • Privacy
website-boston WebsiteBoston